Atherosclerosis pathophysiology and the role of novel risk factors: A clinicobiochemical perspective

被引:156
作者
Mallika, V. [1 ]
Goswami, Binita
Rajappa, Medha
机构
[1] GB Pant Hosp, Dept Biochem, New Delhi 110002, India
[2] Maulana Azad Med Coll, Dept Biochem, New Delhi, India
[3] AIIMS, Dr RP Ctr Ophthalm Sci, Dept Ocular Biochem, New Delhi, India
关键词
D O I
10.1177/0003319707303443
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Atherosclerosis is the root cause of the biggest killer of the 21(st) century. Mechanisms contributing to atherogenesis are multiple and complex. A number of theories-including the role of dyslipidemia, hypercoagulability, oxidative stress, endothelial dysfunction, and inflammation and infection by certain pathogens-have been propounded from time to time explain this complex phenomenon. Recently it has been suggested that atherosclerosis is a multifactorial, multistep disease that involves chronic inflammation at every step, from initiation to progression, and that all the risk factors contribute to pathogenesis by aggravating the underlying inflammatory process. A better understanding of the pathogenesis of atherosclerosis will aid in devising pharmaceutical and lifestyle modifications for reducing mortality resulting from coronary artery disease (CAD). A comprehensive literature search was conducted using the Web sites of the National Library of Medicine (http://www.ncbl.nlm.nih.gov/) and PubMed Central, the US National Library of Medicine's digital archive of life sciences literature (http://www.pubmedcentral.nih.gov/). The data were accessed from books and journals in which relevant articles in this field were published. The whole spectrum of coronary artery disease evolves through various events that lead to the formation and progression of atherosclerotic plaque and finally its complications. Atherosclerosis is the culprit behind coronary artery disease, cerebral vascular disease, and peripheral vascular disease. The pathogenic mechanisms are varied and complex. Of late, the role of lipoprotein (a), homocysteine, and inflammation and infection as prime culprits in pathogenesis of CAD is the subject of intense research and debate. The appreciation of the role of inflammation in atherosclerosis provides a mechanistic framework to understand the clinical benefits of newer therapeutic :strategies, and a better understanding of pathogenesis aids in formulating preventive and therapeutic strategies in reducing mortality resulting from CAD. An in-depth knowledge of the various pathogenic mechanisms involved in atherosclerosis can help in :substantiating the current existing knowledge about the CAD epidemic. This knowledge will help clinicians to better manage the disease, which affects Indians in its most severe form.
引用
收藏
页码:513 / 522
页数:10
相关论文
共 93 条
[31]   IMMUNE-MECHANISMS IN ATHEROSCLEROSIS [J].
HANSSON, GK ;
JONASSON, L ;
SEIFERT, PS ;
STEMME, S .
ARTERIOSCLEROSIS, 1989, 9 (05) :567-578
[32]   HOMOCYSTEINE AND OTHER SULFHYDRYL COMPOUNDS ENHANCE THE BINDING OF LIPOPROTEIN(A) TO FIBRIN - A POTENTIAL BIOCHEMICAL LINK BETWEEN THROMBOSIS, ATHEROGENESIS, AND SULFHYDRYL COMPOUND METABOLISM [J].
HARPEL, PC ;
CHANG, VT ;
BORTH, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) :10193-10197
[33]  
Harrison D, 2003, AM J CARDIOL, V91, p7A
[34]   ROLE OF TRIGLYCERIDE-RICH LIPOPROTEINS IN PROGRESSION OF ATHEROSCLEROSIS [J].
HAVEL, RJ .
CIRCULATION, 1990, 81 (02) :694-696
[35]   Hyperhomocysteinemia, vascular function and atherosclerosis: Effects of vitamins [J].
Haynes, WG .
CARDIOVASCULAR DRUGS AND THERAPY, 2002, 16 (05) :391-399
[36]  
HEINECKE JW, 1987, J BIOL CHEM, V262, P10098
[37]  
HILTUNEN MO, 2000, ARTERIOSCLER THROMB, V20, P1557
[38]   TRIGLYCERIDE-RICH AND CHOLESTEROL-RICH LIPOPROTEINS HAVE A DIFFERENTIAL EFFECT ON MILD/MODERATE AND SEVERE LESION PROGRESSION AS ASSESSED BY QUANTITATIVE CORONARY ANGIOGRAPHY IN A CONTROLLED TRIAL OF LOVASTATIN [J].
HODIS, HN ;
MACK, WJ ;
AZEN, SP ;
ALAUPOVIC, P ;
POGODA, JM ;
LABREE, L ;
HEMPHILL, LC ;
KRAMSCH, DM ;
BLANKENHORN, DH .
CIRCULATION, 1994, 90 (01) :42-49
[39]   Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease [J].
Holvoet, P ;
Mertens, A ;
Verhamme, P ;
Bogaerts, K ;
Beyens, G ;
Verhaeghe, R ;
Collen, D ;
Muls, E ;
Van de Werf, F .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (05) :844-848
[40]   Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study) [J].
Hulthe, J ;
Fagerberg, B .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (07) :1162-1167